NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced that the Somerset NHS Foundation Trust (FT) is the first NHS trust in the United Kingdom, and the first non-private sector organisation in the world, to introduce the Allurion Gastric Balloon - the world's only swallowable gastric balloon that requires no surgery, no endoscopy and no anaesthesia1. Once swallowed, the balloon is filled and remains in the stomach for approximately 4 ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE:ALUR), a company dedicated to ending obesity, today announced further expansion of its Virtual Care Suite (VCS) digital platform with new commercial agreements signed with Lazeo, France's largest aesthetic and weight loss clinic chain, and Transform, UK's largest aesthetic and weight loss clinic chain. After recently expanding its commercial agreement with Weight Doctors®—Germany’s leading group of private clinics and centers for weight loss ...

Financial Data and Key Metrics Changes - Allurion generated $18.2 million in revenue for Q3 2023, representing a 13% increase year-over-year and a 40% sequential increase from Q2 2023 [5][15] - Gross margins were 77% compared to 78% for the same period a year ago [15] - Loss from operations for Q3 was $26.2 million, compared to $12 million in the year-ago period, which includes $10 million in transaction-related expenses and stock-based compensation [15][16] - Cash and cash equivalents at September 30, 2023, were $79.9 million, an increase of $72 million from December 31, 2022 [16] Business Line Data and Key Metrics Changes - Sales and marketing expenses decreased by $1.7 million or 11% for the quarter, driven by delayed investments during the business combination with Compute Health [15] - Research and development expenses increased by $2.1 million or 42% related to costs incurred in the AUDACITY FDA study [15] Market Data and Key Metrics Changes - The company is currently active in over 50 countries but has yet to enter the United States [13] - The rise of GLP-1 drugs is expected to create a $100 billion market for weight loss solutions by 2030, which may drive more patients towards medical weight loss providers [12] Company Strategy and Development Direction - Allurion aims to expand globally while optimizing resource allocation to maximize returns on investments [13] - The company is focusing on enhancing its AI platform and improving patient outcomes through initiatives like the Virtual Care Suite and Coach Iris [18] - A partnership with Medtronic is expected to help expand access to the Allurion program and enhance the management of bariatric surgery patients [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged headwinds in the medtech sector, including lower consumer spending and geopolitical unrest, which may impact elective procedures [17] - Despite short-term challenges, the long-term growth potential in the obesity market remains strong, with a proven technology and program [37] Other Important Information - The Allurion program includes a gastric balloon technology and a virtual care suite that supports patient monitoring and behavior change [7][9] - The company has completed enrollment in the AUDACITY trial ahead of schedule, which is designed to support a pre-market approval application for the Allurion balloon [13][22] Q&A Session Summary Question: What impact do GLP-1 drugs have on Allurion's business? - Management believes GLP-1 drugs will serve as a tailwind by raising awareness around obesity and driving patients to seek medical weight loss solutions [20] Question: How does Allurion fit into the bariatric surgery market? - Allurion targets patients who qualify for bariatric surgery but prefer non-invasive options, showing significant weight loss results in high BMI populations [22] Question: Is there potential for partnerships with pharmaceutical companies? - The company is open to exploring partnerships to promote the Allurion program alongside GLP-1 drugs, leveraging its software for patient management [25] Question: What feedback has been received on Coach Iris? - Initial feedback indicates that both patients and providers find Coach Iris helpful for improving engagement and providing 24/7 support [27] Question: How is the Virtual Care Suite being adopted? - The Virtual Care Suite is integrated with the Allurion balloon program, allowing providers to track patients longitudinally and potentially expand its use to non-balloon patients [34]

WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-41767 Allurion Technologies, Inc. (Exact Name of Registrant as Specified in its Charter) ...

Exhibit 99.1 Allurion Reports Third Quarter 2023 Financial Results and Provides Business Update Completed NYSE listing and business combination generating $92M in net proceeds Generated 40% sequential revenue growth in first quarter as a public company Completed enrollment in AUDACITY FDA pivotal trial for Allurion Balloon Launched Coach Iris, a conversational, 24/7, and generative AI-powered weight loss coach Natick, MA – November 13, 2023 – Allurion Technologies, Inc. (NYSE: ALUR) ("Allurion"), a company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each classTrading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share ALUR The New York Stock Exchange Warrants, each exercisable for 1.420455 shares of Common Stock for $8.10 per share ALUR WS The New York Stock Exchange FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITI ...